Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cytokinetics
(NQ:
CYTK
)
52.44
-0.19 (-0.36%)
Streaming Delayed Price
Updated: 2:53 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Cytokinetics
< Previous
1
2
3
4
5
6
7
Next >
CYTK Stock Flies High on Exciting Drug Trial Results
July 19, 2021
CYTK stock is being boosted by bullish biopharma buyers today. The company is reporting with optimism regarding its newest HCM treatment.
Via
InvestorPlace
How Strong Cytokinetics Test Results Could Undermine Bristol Myers' $13.1 Billion Buyout
July 19, 2021
Cytokinetics said Monday its treatment improved blood flow for patients with a genetic heart disease, and the biotech stock sprinted.
Via
Investor's Business Daily
Mid-Morning Market Update: Markets Open Lower; AutoNation Profit Beats Estimates
July 19, 2021
Following the market opening Monday, the Dow traded down 2.31% to 33,885.81 while the NASDAQ fell 1.67% to 14,186.04. The S&P also fell, dropping 1.94% to 4,243.38. The U.S....
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Stocks That Hit 52-Week Highs On Monday
July 19, 2021
On Monday morning, 20 companies achieved new highs for the year. Areas of Significance: The largest company by market cap to break to a new 52-week high was PepsiCo...
Via
Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
May 01, 2021
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...
Via
Benzinga
Exposures
Product Safety
Cytokinetics Shares Gain On Positive Data From Heart Disease Candidate
July 19, 2021
Cytokinetics Incorporated (NASDAQ: CYTK) has announced positive topline results from Cohorts 1 and 2 of REDWOOD-HCM Phase 2 trial of CK-3773274 (CK-274) in...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
July 19, 2021
Gainers NRX Pharmaceuticals (NASDAQ:NRXP) stock moved upwards by 67.6% to $14.28 during Monday's pre-market session. The company's market cap stands at $684.2...
Via
Benzinga
Cytokinetics Post-Hoc Data Suggests Omecamtiv Mecarbil Works Better In High-Risk Patients For Heart Failure
May 17, 2021
Cytokinetics Incorporated (NASDAQ: CYTK) announced secondary data analysis from the GALACTIC-HF trial evaluating omecamtiv mecarbil in patients with heart...
Via
Benzinga
Cytokinetics Inc (CYTK) Q1 2021 Earnings Call Transcript
May 07, 2021
CYTK earnings call for the period ending March 31, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Astellas Walks Away From $450M Research & Discovery Partnership With Cytokinetics
May 03, 2021
Cytokinetics Inc (NASDAQ: CYTK) revealed in an SEC filing that Astellas Pharma Inc (OTCMKTS: ALPMY) is walking away from a pact to research and...
Via
Benzinga
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
May 06, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.